Disc Dynamics gets FDA OK for spinal nucleus replacement trial:
This article was originally published in Clinica
Executive Summary
US firm Disc Dynamics stepped up the race for US approval of a spinal nucleus replacement device for treating back pain in degenerative disc disease (DDD), after this month receiving FDA approval to commence a clinical study of its Dascor Disc Arthroscopy System. Rival company Raymedica received FDA approval to commence clinical trials only last month. Other competitors include Replication Medical, Spine Wave, Cryolife, Disc Anugmentation Technologies and Corin. The Dascor Disc Arthroscopy System has been CE-marked for sale in Europe since 2003 said the Eden Prairie, Minnesota-based firm. Spinal nucleus replacement provides a minimally invasive alternative to spinal fusion and total disc replacement for treating DDD.
You may also be interested in...
Japan Regulatory Update: Revised Law Widens RWD Scope, Price Revisions/Listings
Japan now allows pseudonymized personal data for medical use under a licensing system for wider use of real-world data. Meanwhile, a national cost-effectiveness assessment scheme has slashed reimbursement prices for Lagevrio and Kerendia, and Alexion’s Voydeya has been added to the reimbursement tariff.
Abbott's ‘Bedrock Of Good Health’ Nutritionals Business Faces Mounting Infant Formula Litigation
Nutritional product business had 5.1% Q1 sales growth and is like Abbott’s other segments, “super well-aligned to the global demographics and trends in health care,” says CEO Ford. But as it defends complaints of damages from powder formulas made at facility found with unsafe levels of bacterial contaminants, Abbott’s also targeted in litigation alleging failure to warn about risk of infants born prematurely developing necrotizing enterocolitis if fed cow’s milk-based formula.
‘Core Pillars’ Of Safety And Innovation Take Center Stage In FDA Reports
The US FDA has issued a pair of reports focused on device safety and innovation. The reports describe recent steps the agency has taken to improve in the two areas, and what it plans to do next.